Interestingly, CDK4/6 inhibition was shown to reduce the expression of DNMT1 (encoding DNA methyltransferase 1), an E2F target gene, resulting in hypomethylation of the genome and activation of the expression of endogenous retroviral (ERV) elements and ISGs to enhance tumor antigen presentation and ultimately anti-tumor immunity (53). Here, CDK4 is linked to neoplasm.